Genetically modified msc and therapeutic methods

Abstract

This disclosure relates to vectors, isolated cells, compositions, and methods for the treatment of critical limb ischemia and associated disorders. One aspect of the disclosure relates to a vector comprising a nucleic acid encoding a 165A isoform VEGF protein and a promoter that regulates expression of the nucleic acid encoding the VEGF.

1 . A method for treating peripheral artery disease and/or critical limb ischemia in a patient in need thereof comprising administering to the patient an effective amount of an isolated marrow stromal cell comprising a lentiviral vector, wherein the vector comprises:
 (a) a nucleic acid encoding a 165A isoform VEGF protein or an equivalent thereof, and   (b) a promoter that regulates expression of the nucleic acid encoding the 165A isoform VEGF or an equivalent thereof.